CGC
Canopy Growth Corporation
CGC
Key terms
About CGC
Canopy Growth Corp. engages in the production, distribution, and sale of cannabis and cannabinoid-based products for both adult-use and medical purposes. The firm operates through the following segments: Canada Cannabis, Rest-of-world Cannabis, Storz and Bickel, BioSteel, This Works, and Other. The Canada Cannabis segment includes the production, distribution, and sale of cannabis, hemp, and cannabis products in Canada. The Rest-of-world Cannabis segment focuses on production and sale of cannabis, hemp, and cannabis products internationally. The Storz and Bickel segment produces and sells vaporizers. The BioSteel segment refers to the sale of consumer packaged goods including sports nutrition beverages, hydration mixes, proteins, and other specialty nutrition products. The This Works segment includes the production and sale of beauty, skincare, wellness, and sleep products, some of which have been blended with hemp-derived CBD isolate. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CGC news
Yesterday 8:45am ET Largest borrow rate increases among liquid names by TipRanks Jun 11 4:05pm ET Canopy Growth (CGC) Receives a Hold from Jefferies by TipRanks Jun 06 5:26pm ET Cannabis Stocks Fall as GOP Congressman Opposes Marijuana Banking Protections by TipRanks Jun 06 11:00am ET Rising High: Exclusive talk with cannabis REIT NewLake Capital by TipRanks Jun 06 10:25am ET Canopy Growth call volume above normal and directionally bullish by TipRanks Jun 06 8:43am ET Canopy Growth Launches US$250M Equity Program by TipRanks Jun 06 8:17am ET Canopy Growth establishes $250M at-the-market equity offering program by TipRanks Jun 05 8:06am ET Canopy Growth files automatic mixed securities shelf by TipRanks Jun 04 8:19am ET Canopy Growth Advances Strategic Acquisitions by TipRanks Jun 04 7:52am ET Canopy Growth price target raised to C$11 from C$6 at Alliance Global Partners by TipRanks Jun 04 7:51am ET Canopy Growth announces exercise of Acreage options for Canopy USA acquisition by TipRanks May 31 12:19pm ET Canopy Growth price target lowered to C$4 from C$4.50 at CIBC by TipRanks May 31 10:40am ET Analysts Conflicted on These Healthcare Names: Cytokinetics (CYTK) and Canopy Growth (CGC) by TipRanks May 31 8:19am ET Canopy Growth price target lowered to C$20 from C$25 at Roth MKM by TipRanks May 31 7:10am ET Analysts Conflicted on These Healthcare Names: Cooper Co (COO), Canopy Growth (CGC) and BioMarin Pharmaceutical (BMRN) by TipRanks May 31 5:16am ET Canopy Growth’s Strategic Positioning and Market Potential Propel Positive Analyst Outlook by TipRanks May 31 5:10am ET Canopy Growth price target lowered to C$20 from C$25 at Roth MKM by TipRanks May 31 2:00am ET Canopy Growth’s Battle Against Unregulated Cannabis Rivals: A Threat to Market Fairness and Financial Stability by TipRanks May 30 11:10pm ET Analysts Conflicted on These Healthcare Names: Canopy Growth (CGC), Ultragenyx Pharmaceutical (RARE) and Roivant Sciences (ROIV) by TipRanks May 30 11:20am ET Rising High: Exclusive talk with funding solutions provider FundCanna by TipRanks May 30 10:25am ET Canopy Growth call volume above normal and directionally bullish by TipRanks May 30 7:50am ET Canopy Growth Reveals Strong Q4 Financials by TipRanks May 30 7:49am ET Canopy Growth Celebrates Strong Q4 Revenue Growth by TipRanks May 30 7:05am ET Canopy Growth says no material debt obligation due until March 2026 by TipRanks May 30 7:05am ET Options Volatility and Implied Earnings Moves Today, May 30, 2024 by TipRanks May 30 7:04am ET Canopy Growth reports Q4 EPS (C$1.03) vs. (C$12.83) last year by TipRanks May 27 7:00am ET Options Volatility and Implied Earnings Moves This Week, May 28 – May 30, 2024 by TipRanks May 23 11:02am ET Rising High: Exclusive talk with MSO Ascend Wellness by TipRanks May 17 12:14pm ET Biden’s Marijuana Rescheduling: What It Means for Investors by TipRanks May 17 5:19am ET Canopy Growth Sell Rating Justified by Stagnant Sales, High Valuation, and Profitability Concerns by TipRanks May 16 12:52pm ET DOJ set to post plans for marijuana reclassification, Politico says by TipRanks
No recent press releases are available for CGC
CGC Financials
1-year income & revenue
Key terms
Ad Feedback
CGC Forecasts
analyst rating
- buy
- hold
- sell
We're sorry, but this
information is
temporarily unavailable.
1-year stock price forecast
CGC Competitors
$ Market cap P/E ratio $ Price 1d change 52-week range
